Cite
HARVARD Citation
Wannesson, B. et al. (n.d.). High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). Hematological oncology. p. 320. [Online].